Clinical TrialApr 21, 2026, 07:01 AM
BioAge BGE-102 Phase 1 Shows ">=85%" hsCRP Reduction; Phase 2 Planned
AI Summary
BioAge Labs reported positive Phase 1 clinical trial results for BGE-102, an NLRP3 inhibitor. Both 60 mg and 120 mg once-daily doses achieved at least 85% median hsCRP reductions in participants with obesity and elevated inflammation, demonstrating potential best-in-class efficacy and a favorable tolerability profile. Based on these results, BioAge plans to initiate a Phase 2 cardiovascular risk trial and a Phase 1b/2a diabetic macular edema trial in mid-2026, with data anticipated by end of 2026 and mid-2027, respectively.
Key Highlights
- BGE-102 achieved ">=85%" median hsCRP reductions in obesity patients.
- 60 mg and 120 mg once-daily doses showed comparable hsCRP reductions.
- BGE-102 was well tolerated across all dose levels in Phase 1 trial.
- Phase 2 cardiovascular risk trial to initiate mid-2026, results by end of 2026.
- Phase 1b/2a DME trial to initiate mid-2026, results by mid-2027.